医学
内科学
肿瘤科
随机对照试验
年轻人
癌症
临床试验
物理疗法
作者
Valerie McLaughlin Crabtree,Kayla LaRosa,Erin MacArthur,Kathryn Russell,Fang Wang,Hui Zhang,Haitao Pan,Jane Brigden,Laura E. Schwartz,Matthew W. Wilson,Alberto S. Pappo
标识
DOI:10.1080/15402002.2020.1797744
摘要
Objective/Background Fatigue is one of the most consistent and distressing symptoms reported by adolescent/young adult (AYA) oncology patients. Bright white light (BWL) is used to treat fatigue in adult oncology but has not been explored in AYA oncology patients. The purpose of the current study was to determine the feasibility and acceptability of BWL for AYA who were receiving cancer-directed therapy.Participants 51 AYA patients with newly diagnosed solid tumors, including lymphoma.Methods Participants were randomized to dim red light (DRL, n = 25) or BWL (n = 26) from devices retrofitted with adherence monitors for 30 minutes upon awakening daily for 8 weeks. Side effects were assessed via modified Systematic Assessment for Treatment-Emergent Effects (SAFTEE). Participants completed the PedsQL Multidimensional Fatigue Scale.Results Of patients approached, 73% consented and participated. Mean adherence was 57% of days on study with 30.68 average daily minutes of usage. BWL did not cause more extreme treatment-emergent effects over DRL. Patients in the BWL group demonstrated significant improvement on all fatigue outcomes by both self-report and parent proxy report, which was not observed in the DRL group.Conclusions This is the first study to evaluate the feasibility and acceptability of light therapy to reduce fatigue in AYA patients receiving cancer-directed therapy. These findings demonstrate the feasibility and acceptability of the intervention and provide preliminary evidence of the potential benefits of BWL, which warrants further study in a confirmatory efficacy trial.ClinicalTrials.gov Identifier Number: NCT02429063
科研通智能强力驱动
Strongly Powered by AbleSci AI